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Abstract: Mitral valve prolapse (MVP) is the most common cause of severe mitral regurgitation. It has
been reported that MVP patients—candidates for mitral valve repair (MVRep)—showed an alteration
in the antioxidant defense systems as well as in the L-arginine metabolic pathway. In this study,
we investigate if oxidative stress and endothelial dysfunction are an MVP consequence or driving
factors. Forty-five patients undergoing MVRep were evaluated before and 6 months post surgery and
compared to 29 controls. Oxidized (GSSG) and reduced (GSH) forms of glutathione, and L-arginine
metabolic pathway were analyzed using liquid chromatography-tandem mass spectrometry methods
while osteoprotegerin (OPG) through the ELISA kit and circulating endothelial microparticles
(EMP) by flow cytometry. Six-month post surgery, in MVP patients, the GSSG/GSH ratio decreased
while symmetric and asymmetric dimethylarginines levels remained comparable to the baseline.
Conversely, OPG levels significantly increased when compared to their baseline. Finally, pre-MVRep
EMP levels were significantly higher in patients than in controls and did not change post surgery.
Overall, these results highlight that MVRep completely restores the increased oxidative stress levels,
as evidenced in MVP patients. Conversely, no amelioration of endothelial dysfunction was evidenced
after surgery. Thus, therapies aimed to restore a proper endothelial function before and after surgical
repair could benefit MVP patients.
Keywords: glutathione; osteoprotegerin; oxidative stress; endothelial microparticles; mitral
valve prolapse
1. Introduction
Mitral valve prolapse (MVP) is a debilitating disease afflicting 2% to 3% of people [1,2].
Even though the pathology was first described in the late 1800s [1], no major risk factor has
been identified yet [3]. In addition, despite the fact that several studies have evaluated the
effectiveness of angiotensin-converting enzyme inhibitors [4,5] and beta-blockers [6,7], no recommended
pharmacological therapies for severe mitral regurgitation (MR) with associated MVP have been found.
J. Clin. Med. 2019, 8, 835; doi:10.3390/jcm8060835 www.mdpi.com/journal/jcm
J. Clin. Med. 2019, 8, 835 2 of 13
To date, the diagnostic gold standard is two dimensional (2D) echocardiography [8–10], whereas surgical
intervention is the therapeutic choice when the prolapse causes symptomatic severe regurgitation [11].
The mitral valve has a complex architectural structure, and its maintenance is regulated by valve
interstitial cells, directly producing, secreting, and degrading the extracellular matrix [1]. In addition,
the monolayer of valve endothelial cells, covering the entire surface of the leaflets, plays an important
role in the homeostasis of the interstitial cells [12]. Thus, when endothelial dysfunction occurs, this tight
regulation is disrupted, leading to MVP [5,6].
In this context, we previously reported that MVP patients with severe regurgitation showed
an impairment in the L-arginine (Arg)/nitric oxide (NO) biosynthetic pathway when compared to
healthy subjects [13]. Furthermore, it has also been demonstrated that endothelial microparticles (EMP)
increase in mitral valve disease and impair mitral valve endothelial function [14], supporting the role
of these subcellular fragments as surrogate markers of endothelial dysfunction [15].
MVP is primarily caused by myxomatous mitral valve degeneration, a process characterized
by an increment of the thickness of valve leaflets and the loss of their well-organized structure.
This process is directly caused by proteoglycans accumulation and structural alteration of collagen [16].
These alterations could be caused by transforming growth factor-b superfamily proteins and by a
weakening of the antioxidant defense systems [17–19].
Previously, we have shown altered systemic oxidative stress homeostasis as well as increased
osteoprotegerin (OPG) plasma levels in MVP patients when compared to controls [20]. In particular,
circulating OPG and oxidative stress status were positively associated with severe mitral regurgitation
due to MVP. Based on these premises, we developed a multivariable regression model, combining OPG
with oxidative stress markers, which were able to discriminate MVP patients from healthy subjects
with high accuracy and precision [20]. These results are in accordance with the pivotal role played by
OPG during the endothelial-to-mesenchymal transition (EndMT) [21], a process known to be linked
to MVP [22,23]. In particular, endothelial cells, during EndMT, increased production and secretion
of OPG that in turn contributed to the extracellular matrix alterations involved in MVP progression.
These data underlined OPG contribution in disease progression by interfering with the correct valve
endothelial function [21].
Indeed, it has been hypothesized that both alterations in oxidative stress status and in endothelial
function were associated with MR; however, up to now no data regarding these processes in MVP
patients after surgical restoration of normal valve function is available.
Given this background, the aim of the present study is to investigate if surgical intervention is able
to restore, to some extent, the systemic alterations evidenced in MVP patients before surgery, elucidating
if oxidative stress and endothelial dysfunction are an MVP consequence or the driving factors.
2. Experimental Section
2.1. Patient Demographics
This prospective observational study was approved by the IRCCS Centro Cardiologico Monzino
(CCM) Institutional Review Board and by the IRCCS Istituto Europeo di Oncologia and CCM Ethics
Committee. The investigation conformed to the principles outlined in the Declaration of Helsinki
(1964) and informed consent was obtained from all the participants. Over one year period (June
2016–June 2017), 45 patients undergoing mitral valve repair (MVRep), due to primary posterior MVP
with severe MR, were enrolled. The preoperative inclusion criteria were the need for elective, isolated
surgical procedure, over 18 year of age, ejection fraction >30%, normal sinus rhythm, and no history of
atrial fibrillation. Patients with premature menopause and/or osteoporosis, secondary MVP, previous
aortic or mitral valve surgery, rheumatic heart disease, endocarditis, active malignancy, chronic liver
failure, calcium regulation disorders (hyperparathyroidism, hyperthyroidism, and hypothyroidism),
and chronic or acute inflammatory states (corticosteroid intake, sepsis, autoimmune disease,
inflammatory bowel disease, and c-reactive protein >5.0 mg/L, respectively) were excluded. To make a
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comparison, during the same time-period we also enrolled 29 controls with cardiovascular risk factors
similar to MVP patients, selected from those attending the clinic for global control of cardiovascular
risk at CCM. For controls’ selection, we took into account the following cardiovascular risk factors: age,
sex, diabetes, hypertension, hypercholesterolemia, and smoking habits. All subjects were assessed with
detailed medical history, physical examination, and echocardiography. In all patients, blood collection
was performed before coronary angiography with the exception of the controls that underwent sample
collection at a scheduled visit.
2.2. Echocardiography Evaluation
Two-dimensional (2D) echocardiography represents the gold standard for diagnosis and
assessment of MVP patients [9,24]. The combination of 2D and 3D echocardiographic imaging
provides detailed morphological and functional assessment of mitral valve itself [8,25]. Experienced
cardiologists of CCM performed the echocardiography scans, according to the current guideline
recommendations [9,24]. Echocardiographically, MVP is defined as a single or bileaflet prolapse,
at least 2 mm beyond the long-axis annular plane, while the assessment of the severity of MR relies on
a multiparametric evaluation [10,26]. The included parameters are left ventricular ejection fraction
(LVEF), left ventricular diastolic and systolic volumes (mL), left atrial area (cm2), pulmonary artery
systolic pressure (PAP), and effective regurgitant orifice area (EROA).
2.3. Blood Sampling
Whole blood: 6 mL of peripheral blood sample was drawn from patients and controls while
fasting, into tubes containing EDTA (9.3 mM; Vacutainer Systems, Becton Dickinson, Franklin Lakes,
NJ, USA) kept on ice. Two hundred fifty µL of whole blood was immediately precipitated with 250 µL
of 10% trichloroacetic acid (Sigma-Aldrich, St Louis, MO, USA) plus 1 mM EDTA solution. Samples
were stored at −80 ◦C until analysis.
Plasma EDTA: anti-coagulated blood was centrifuged at 1700× g for 10 min at 4 ◦C within 30 min
after being drawn. Plasma was separated, and aliquots were stored at −80 ◦C until analysis.
Plasma citrate: sodium citrate anti-coagulated blood was centrifuged at 1700× g for 10 min at 4 ◦C
within 30 min after being drawn to obtain platelet-poor plasma (PPP). PPP was collected, and aliquots
were stored at −80 ◦C until analysis.
The analysis of whole blood and plasma EDTA, from MVP patients and controls, was performed
in a 3 months window, and all subsequent analyses were performed in duplicates in order to avoid
measurement biases. A flow cytometry expert blinded from subject category (control, pre-operative
MVP, or post-operative MVP) performed EMPs analysis on plasma citrate.
2.4. Oxidative Stress Measurement
For oxidative stress evaluation, we measured the levels of the oxidized (GSSG) and the reduced
(GSH) forms of glutathione, whose ratio is a well recognized oxidative stress index (GSSG/GSH) [27].
Whole blood concentrations of GSSG and GSH were quantified using a previously developed
and validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method [28]. Briefly,
chromatographic separation was conducted on a Luna PFP analytical column (100 × 2.0 mm, 3 µm,
Phenomenex, Torrance, CA, USA), eluted at 35◦C under isocratic conditions at 200 µL/min by 1%
methanol in ammonium formate 0.75 mM adjusted to pH 3.5 with formic acid. Analysis was performed
by Accela chromatographic system coupled with a triple quadrupole mass spectrometer TSQ Quantum
Access (Thermo Fisher Scientific, San Jose, CA, USA) using electrospray ionization source in positive
ion mode. The transitions used in the multiple reaction monitoring were m/z 308.1→m/z 76.2 + 84.2 +
161.9 for GSH and m/z 613.2→m/z 230.5 + 234.6 + 354.8 for GSSG. Data were obtained after comparison
with calibration curves using GSH and GSSG standard solutions (Sigma-Aldrich). The intra- and
inter-day CVs % obtained with standard samples were <5% for the both the analytes considered.
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The limits of detection (LOD) were 0.031 µmol/L and 0.008 µmol/L for GSH and GSSG, respectively.
Levels of GSH and GSSG were corrected for hemoglobin (Hb) and expressed as µmol/g Hb.
2.5. Antioxidants
To evaluate the antioxidant defense system, plasma vitamin E (α-tocopherol (αT) and γ-tocopherol
(γT)) was measured by high-performance liquid chromatography equipped with fluorimetric detector
FP-1520, after organic extraction, as previously described by Werba et al. [29]. Briefly, 100 µL of plasma
sample was precipitated with ethanol 50%, and α- and γT were extracted with 1 mL of n-hexane.
After evaporation to dryness under nitrogen stream of 600 µL of organic extract, the residue was
dissolved in ethanol (200 µL). An aliquot (25 µL) was separated using a Discovery C18, 3.5 µm RP
column (4.6 mm × 250 mm) (Supelco, College Park, GA, USA) eluted with methanol (100%) as mobile
phase at flow rate of 1 mL/min. Analysis was carried out by Jasco (Tokyo, Japan) FP15-20 fluorescent
detector (λecc 292 nm, λem 335 nm). ESA commercial software was used for chromatograms integration.
Data were obtained after comparison with calibration curves using α- and γT pure standard solutions
(Sigma-Aldrich). The intra- and the inter-day CVs %s for plasma αT were 3.3% and 4.0%, respectively,
with a limit of quantification (LOQ) of 0.38 µmol/L. The corresponding values for γT were 3.3% and
4.7%, respectively, with a LOQ of 0.014 µmol/L.
2.6. Osteoprotegerin Evaluation
Plasma EDTA was used to measure levels of soluble OPG with an enzyme-linked immunosorbent
assay (ELISA) kit (DuoSet–R&D, Minneapolis, MN, USA) following manufacturer instructions and
previously validation [20]. The standard of this kit is similar to full-length OPG, making this ELISA kit
more representative of circulating OPG molecule [30]. The intra- and the inter-day CVs %s for plasma
OPG were 4.2% and 14.2%, respectively.
2.7. L-Arginine Metabolic Pathway Evaluation
For the assessment of L-arginine metabolic pathway, we simultaneously measured plasma
levels of Arg, L-citrulline (Cit), L-ornithine (Orn), asymmetric (ADMA), and symmetric (SDMA)
dimethylarginines by LC-MS/MS using a target metabolomic approach [31]. The ratio (Arg/(Orn+
Cit)) was calculated and used as an index of global arginine bioavailability (GABR) [32,33].
Briefly, chromatographic analysis was conducted on a Luna HILIC (hydrophilic interaction liquid
chromatography) analytical column (50 × 2.0 mm, 3 µm, Phenomenex, Torrance, CA, USA). The mobile
phases consisted of aqueous 1.5 mM ammonium formate (pH 3.2) (A) and 1.5 mM ammonium formate
in acetonitrile/methanol (95.5:0.5, v/v) (pH 3.2) (B) at flow rate of 250 µL/min. The mobile phase gradient
ran from 10% A to 70% A over 7 min, ran from 70% A to 94.5% A over 2 min, and was held at 94.5% A
for 5 min, returning to 10% A over 2 min and held at 10% A for re-equilibration. The sample injection
volume was 10 µL, the column temperature was set at 30 ◦C, and the sample injector was maintained
at 10◦C. Total run time per sample, including column cleaning and re-equilibration, was 25 min.
Mass spectrometric analysis was performed using a TSQ Quantum Access (Thermo Fisher Scientific)
triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) interface operated
in positive mode. The analytes were detected by tandem mass spectrometry (MS/MS) using multiple
reaction monitoring (MRM). The LOQ value was ≤0.25 µM for all compounds, making this method
suitable for the analysis of samples containing relatively low concentrations of the analytes, with a
satisfactory precision as documented by the intra- and inter-day CVs of less than 10%. The method was
linear in a wide range of concentrations (between 0 and 20 µM), with correlation coefficients greater
than 0.99 and LOD around 3–10 nM for all compounds.
2.8. Endothelial Microparticle (EMP) Identification
The frozen PPP was thawed at 37 ◦C for 3 min and then centrifuged at 13,000 g for 5 min to
obtain platelet-free plasma (PFP). Sixty µL of PFP was diluted with 118 µL of 0.22 µm-pore-size-
J. Clin. Med. 2019, 8, 835 5 of 13
membrane-filtered PBS 1X (Gibco, Thermo Fisher Scientific) and then incubated with 2 µL of calcein
AM 10 µM (Thermo Fisher Scientific) for 25 min at 37 ◦C in the dark in order to stain intact
MPs. Afterwards, saturating concentration of an antibody against CD146, an endothelial-derived
microparticles marker, conjugated with phycoerythrin (Becton Dickinson Bioscience), was added for
15 min at room temperature in the dark. Samples were then analysed by flow cytometry (Gallios,
Beckman Coulter, Brea, CA, USA) using Megamix-Plus SSC beads (0.5, 0.9, and 3 µm, BioCytex,
Marseille, France) to define the analysis gate. Representative images of flow cytometry workflow are
reported in Supplemental Figure S1.
2.9. Statistical Analysis
Continuous variables were summarized as mean ± standard deviation (SD), while categorical
variables were summarized as frequency (n) and percentage (%). Patient characteristic continuous
variables were analysed by Student’s t-test, while discrete ones were analysed by Fisher’s exact test.
Plasma biomarkers were first compared between controls and MVP patients by general linear models.
As there were major differences in the clinical features in the study groups, three statistical models
with different levels of adjustment for baseline clinical features were employed: Model 1, unadjusted;
Model 2, adjusted for body mass index; and Model 3, adjusted for body mass index and treatment
with anti-hypertensive drugs. To evaluate differences between pre- and post-operative MVP biological
variables, a multivariate model taking into account repeated measurements was implemented. All the
analyses were performed using IBM SPSS Statistic v25 (International Business Machines Corporation,
New York, NY, USA), and images were created with Graphpad Prism v7.0 (GraphPad Software,
San Diego, CA, USA).
3. Results
3.1. Patient Characteristics
Demographic, laboratory, and drug therapies of the study population are listed in Table 1.
Body mass index was significantly lower in MVP patients than in controls, as reported by other
authors [2]. In addition, a significant difference in the use of beta-blockers between the two groups
was reported (p = 0.001).
Table 1. Patient characteristics.
Variable Control (n = 29) MVP (n = 45) p-Value
Age (years) 57.3 ± 11.2 61.0 ± 11.5 0.18
Sex (male) 19 (65.5%) 31 (69%) 0.80
Diabetes, n (%) 3 (10.3%) 4 (8.9%) 1.00
Hypertension, n (%) 14 (48.3%) 17 (37.8%) 0.47
Dyslipidemia, n (%) 14 (48.3%) 27 (60.0%) 0.35
Smokers, n (%) 6 (20.7%) 5 (11.1%) 0.32
BMI (Kg/m2) 27.2 ± 4.0 24.8 ± 2.8 0.003
Total Cholesterol (mg/dL) 215.4 ± 38.8 214.1 ± 46.8 0.90
Triglycerides (mg/dL) 113.4 ± 48.1 109.1 ± 43.1 0.69
HDL (mg/dL) 55.7 ± 16.6 51.1 ± 13.0 0.19
LDL (mg/dL) 137.0 ± 37.4 132.0 ± 44.9 0.62
Drug Therapies
Antiplatelets, n (%) 1 (3.4%) 3 (6.7%) 1.00
Angiotensin receptor blockers, n (%) 4 (13.8%) 3 (6.7%) 0.42
Converting enzyme inhibitors, n (%) 5 (17.2%) 15 (33.3%) 0.18
Calcium channel blockers, n (%) 3 (10.3%) 3 (6.7%) 0.67
Beta-blockers, n (%) 1 (3.4%) 17 (37.8%) 0.001
Nitrates, n (%) 0 (0%) 1 (2.2%) 1.00
Statins, n (%) 6 (20.7%) 7 (15.6%) 0.76
BMI: body mass index; HDL: high-density lipoprotein; and LDL: low-density lipoprotein. Continuous variables are
represented as mean ± SD.
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As expected, the qualitative and quantitative pre-operative echocardiographic characteristics
(Table 2), such as the left ventricular diastolic and the systolic volumes, were significantly increased in
MVP patients compared to controls (both p < 0.001). Likewise, the left atrial area and the pulmonary
artery systolic pressure were significantly greater in MVP patients than in controls (p < 0.001), while the
ejection fraction (LVEF) was comparable between the two groups. In addition, most MVP patients
presented chordal rupture that is a near universal finding in this class of patients [34]. The post-operative
echocardiographic characteristics were significantly reduced when compared to the pre-operative ones
(p < 0.01); however, all post-operative variables besides pulmonary artery systolic pressure remained
significantly higher than those measured in controls (p < 0.05), with the exception of LVEF. Overall,
98% of patients (n = 44) underwent successful MVRep (i.e., residual regurgitation less than mild).
This high percentage of successful repair prevented us from making any meaningful comparison with
patients with residual mitral regurgitation.
Table 2. Echocardiographic data of control subjects and patients that underwent mitral valve repair.
Control (n = 29) MVP (n = 45)
Variable Pre-Operative Post-Operative (6 Months)
LVEF, % 66.6 ± 5.7 62.9 ± 9.8 58.0 ± 7.6 #,§
Left Ventricular Diastolic Volume, mL 79.5 ± 23 137.5 ± 30.9 * 100.7 ± 30.4 #,§
Left Ventricular Systolic Volume, mL 26.2 ± 8.1 51.6 ± 20.2 * 43.8 ± 19.1 #,§
Left Atrial Area, cm2 18.4 ± 4.0 29.8 ± 8.4 * 25.7 ± 5.6 #,§
PAP, mmHg 27.2 ± 4.3 34.1 ± 8.3 * 28.8 ± 6.2 #
EROA, cm2 - 0.6 ± 0.2 -
MAC (%) - 8 (18) -
Chordal Rupture (%) - 32 (71) -
LVEF: left ventricular ejection fraction; PAP: pulmonary artery systolic pressure; EROA: effective regurgitant orifice
area; and MAC: mitral annulus calcification. Continuous variables are represented as mean ± SD. * p < 0.001 vs.
controls; # p < 0.01 vs. pre-operative; and § p < 0.05 vs. controls.
In Supplemental Table S1 are depicted the surgical procedural characteristics and post-operative
clinical data of the MVP patients included in this study.
3.2. Oxidative Stress Status Assessment and Antioxidant Defence System Evaluation
The evaluation of oxidative stress status has been performed by the assessment of GSSG/GSH
ratio [27]. At baseline, the levels of this recognized oxidative stress index were significantly higher
in MVP than in controls (p = 0.001—Table 3). Six months after the intervention, we found that this
ratio was significantly decreased in MVP patients (0.11 ± 0.06 at baseline vs. 0.07 ± 0.07 at 6 months
post surgery, p = 0.008—Figure 1A). In addition, αT, the main vitamin E form involved in the thiol
redox cycle, which involves recycling GSH intracellular concentrations [35], showed a trend toward a
reduction in MVP patients at baseline compared to controls (p = 0.056—Table 3).
Six months post-surgery, we noticed a significant increment ofαT levels in MVP patients compared
to their baseline (12.4 ± 2.4 vs. 13.1 ± 3.3 µg/mL, respectively; p = 0.05), becoming similar to αT levels
in controls (13.9 ± 2.9 µg/mL—Figure 1B).
In parallel to glutathione and vitamin E evaluation, we also evaluated Orn levels, the product
of arginase enzyme, whose activity is upregulated by a high oxidative status [36]. MVP patients,
compared to controls, showed a trend toward an increment in Orn levels (p = 0.141—Table 3).
Six months post surgery, Orn concentrations significantly dropped compared to baseline (68.5 ±
24.4 µM vs. 57.6 ± 15.2 µM, respectively; p = 0.001), being similar to those measured in controls (56.8 ±
13.0 µM—Figure 1C).
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Table 3. Circulating biomarkers.
Oxidative Stress Model a Control (n = 29) MVP (n = 45) p-Value
GSSG/GSH 1 0.05 (0.02, 0.07) 0.11 (0.09, 0.13) <0.0001
2 0.04 (0.02, 0.07) 0.11 (0.09, 0.13) <0.0001
3 0.04 (0.01, 0.07) 0.12 (0.09, 0.14) 0.001
α-tocopherol 1 13.87 (12.91, 14.84) 12.35 (11.58, 13.12) 0.017
2 13.8 (12.8, 14.8) 12.4 (11.6, 13.19) 0.048
3 13.59 (12.55, 14.64) 12.53 (11.71, 13.35) 0.056
L-ornithine 1 56.84 (49.16, 64.51) 68.51 (62.35, 74.67) 0.021
2 57.26 (49.29, 65.23) 68.24 (61.91, 74.57) 0.064
3 57.42 (48.98, 65.87) 68.13 (61.54, 74.72) 0.141
Endothelial function Model a Control (n = 29) MVP (n = 45) p-Value
Osteoprotegerin 1 1109.3 (912.0, 1306.5) 1733.6 (1575.2, 1891.9) <0.0001
2 1111.34 (906.1, 1316.58) 1732.26 (1569.36, 1895.17) <0.0001
3 1143.97 (928.08, 1359.86) 1711.24 (1542.68, 1879.8) <0.0001
GABR 1 0.99 (0.89, 1.09) 0.83 (0.75, 0.91) 0.020
2 0.98 (0.88, 1.09) 0.83 (0.75, 0.92) 0.068
3 1 (0.89, 1.1) 0.83 (0.74, 0.91) 0.126
γ-tocopherol 1 0.64 (0.57, 0.71) 0.4 (0.34, 0.46) <0.0001
2 0.64 (0.56, 0.71) 0.4 (0.34, 0.46) <0.0001
3 0.63 (0.55, 0.72) 0.4 (0.34, 0.46) <0.0001
ADMA 1 0.44 (0.41, 0.48) 0.51 (0.48, 0.54) 0.006
2 0.45 (0.41, 0.49) 0.5 (0.48, 0.53) 0.009
3 0.47 (0.43, 0.5) 0.49 (0.47, 0.52) 0.001
SDMA 1 0.42 (0.38, 0.46) 0.49 (0.45, 0.52) 0.016
2 0.41 (0.37, 0.45) 0.49 (0.46, 0.53) 0.011
3 0.47 (0.43, 0.5) 0.49 (0.47, 0.52) 0.009
Continuous variables are represented as mean and 95% confidence interval. a Model 1 = unadjusted; Model 2 = adjusted
for body mass index; and Model 3 = adjusted for body mass index and treatment with anti-hypertensive drugs.
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Figure 1. Oxidative s res status evaluation. (A) i ative stress index ( SSG/GSH) ratio in whole
blood, (B) α-tocopherol, and (C) L-ornithi e levels in plasma. All the analyses were perf r ed in mitral
valve prolapse (MVP) patients (n = 45) before (baseline) and 6 months after surgery and in controls
(CTRL, n = 29) at the time of the visit at the clinic (CCM). Data are reported as mean ± 95% confidential
interval. ** p ≤ 0.01 vs. CTRL; ### p ≤ 0.001, ## p ≤ 0.01, and # p ≤ 0.05 vs. MVP at baseline.
3.3. Endothelial Function Evaluation
Circulating levels of OPG, ADMA, SDMA, GABR, γT, and EMPs were used as surrogate markers
of endothelial function.
At b seline, OPG levels were significantly higher in MVP p ti nts han in controls (p < 0.0001—Table 3
and Figure 2A), while GABR showed a tren toward a reduction in MVP when compared to controls
(p = 0.126—Table 3, Table S2, and Figure 2B). γT was significantly lower in MVP than in controls
(p < 0.0001—Table 3 and Figure 2C). In addition, both ADMA and SDMA were significantly increased
in patients compared to controls (both p < 0.01—Table 3 and Figure 2D,E). At 6th month post surgery,
OPG (post-op: 1974 ± 800.1 vs. pre-op: 1734 ± 653.3 g/mL; p < 0.0001—Figure 2A) and γT levels
(post-op: 0.50 ± 0.22 vs. pre-op: 0.40 ± 0.14 µg/mL; p = 0.001—Figure 2C) significantly incre sed when
compared to their baseline. GABR index (post-op: 0.85 ± 0.27 vs. pre-op: 0.84 ± 0.27 µM—Figure 2B
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and Table S2), ADMA (post-op: 0.49 ± 0.11 vs. pre-op: 0.51 ± 0.11 µM—Figure 2D), and SDMA
(post-op: 0.48 ± 0.12 vs. pre-op: 0.49 ± 0.11 µM—Figure 2E) concentrations, measured at the same time
point, remained comparable to their baseline.J. Clin. Med. 2019, 8, x FOR PEER REVIEW 8 of 13 
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Figure 2. Endothelial function assessment. Plasma levels of (A) osteoprotegerin (OPG), (B) the index of
global L-arginine bioavailability (GABR), (C) γ-tocopherol, (D) asymmetric (ADMA), and (E) symmetric
(SDMA) di thylarginines. All the a alyses were performed in mitral valve prolaps (MVP) patients
(n = 45) before nd 6 months a ter surgery and in controls (CTRL, n = 29). Data are reported as mean
± 95% confidential interval. *** p ≤ 0.001, ** p ≤ 0.01, and * p ≤ 0.05 vs. CTRL; ### p ≤ 0.001 vs.
MVP at baseline.
Finally, we evaluated plasma EMPs at both time points. At baseline, the percentage of circulating
EMPs was significantly higher in MVP patients than in controls (45.7 ± 11.1% vs. 22.5 ± 7.5%,
respectively; p < 0.001—Figure 3) and did not c ange ix months after surgery (49.7 ± 12.5% vs. 45.7 ±
11.1%, respectively—Figure 3). Overall, these results suggest the presence of an endothelial dysfunction
that is not reverted by surgical intervention.
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Figure 3. Plasma circulating CD146+ e t elial microparticles (EMPs). The central line illustrates
the median, while box limit i ic the 25th and 75th percentiles. A l th analys s were performed
in a subgroup of mitral valve prolapse (MVP) patients before (Pre-operative, Pre-OP, n = 10) and 6
months (Post-operative, Post-OP, n = 10) after surgery and in a subgroup of controls (CTRL, n = 10).
*** p ≤ 0.001 vs. CTRL.
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4. Discussion
To the best of our knowledge, this is the first study that evaluates systemic oxidative stress
status and endothelial function before and 6 months after surgical intervention in patients with MVP.
Our results showed that the increased oxidative stress levels detected before surgery significantly
diminished 6 months after the intervention. In contrast, the impairment of vascular function persists
even after valve repair, suggesting a putative link between endothelial dysfunction and MVP aetiology.
MVP with severe MR is the most common cause of mitral valve surgery and one of the most
frequent valve diseases in adults [2]. In this pathological contest, data concerning systemic oxidative
stress status and endothelial dysfunction are limited [13]. Chen et al. [37] identified a possible link
between serum oxidative stress index; atrial contractile dysfunction; and, consequently, atrial fibrillation
in human severe MR.
Experiments performed in canine myxomatous mitral valve disease suggested increased oxidative
stress levels in both plasma and tissues, and endothelial function impairment [38,39]. In this dog
model, genetically predisposed to MR development, the association between mitral valve disease and
declining vascular endothelial function has been confirmed [40].
An important antioxidant system in humans is represented by αT and Γt, which are the two main
forms of vitamin E [35,41]. αT is mainly involved in glutathione recycling, while γT has been shown to
limit the endothelial dysfunction caused by hyperglycemia [42]. In our study, at baseline, both αT and
γT were lower in MVP patients compared to controls. Six months after surgery, αT concentrations
returned to levels comparable to controls, while γT levels remained lower. These results are in
accordance with the ability of mitral valve surgery to completely restore the oxidative stress imbalance
in MVP patients, without improving the endothelial function.
Endothelial dysfunction is now recognized as one of the main triggers for cardiovascular
diseases. Several factors are involved in the development of this phenomenon and, among them,
the bioavailability of Arg. Arginine is the common substrate for both nitric oxide synthase (NOS) and
arginase enzymes, being the sole nitrogen source for NO synthesis [43]. Hence, the counteracting
function of arginase enzyme in NO production and in NO-mediated vasodilatory function plays a key
role. Indeed, arginase, an enzyme that consumes Arg to produce Orn, is increased in inflammatory
and oxidative stress conditions [44]. The high Orn levels found in MVP patients support the concept of
compromised endothelial function and the altered oxidative stress status in MVP patients.
The use of GABR could be an indirect comprehensive marker of the NO biosynthetic pathway,
since it takes into account both the levels of the substrate (Arg) and of its major catabolic products (Orn
and Cit) in vivo [45]. Indeed, diminished GABR is associated with both development of atherosclerosis
and long-term risk for major adverse cardiac events [45]. Other key players in NO synthesis impairment
are represented by two dimethylarginines, namely, SDMA and ADMA. SDMA can inhibit Arg uptake
by blocking the cationic amino acid transporters [46], while ADMA is the major endogenous inhibitor
of NOS [47]. The presence of increased levels of SDMA six months post surgery further supports the
hypothesis of the inability of MVRep to completely resolve the endothelial dysfunction in MVP patients.
Our results showed an increased number of EMPs in MVP patients before surgery, and that these
levels remained high even after MVRep. In line with this, an increased number of plasma EMPs found
in MVP patients leads to Akt/endothelial nitric oxide synthase (eNOS)-HSP90 signaling pathway
inhibition and therefore to mitral valve endothelial dysfunction [14].
Finally, we have previously shown that OPG is involved in the endothelial-to-mesenchymal
transition of endothelial cells isolated from MVP patients [21]. Hence, it could be used as a surrogate
marker of activated endothelial cells prior or during endothelial damage. Our results showed that
OPG levels did not decrease after surgical intervention; rather, they continued to rise.
Some potential limitations of our study need to be discussed. The number of patients is exiguous,
and these data need to be validated in large cohorts. This study is focused only on circulating markers,
and no functional or tissue measurements were performed. In addition, control subjects were evaluated
only at baseline and not followed up; nevertheless, in healthy subjects, the evaluated markers are
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quite stable, thus, it could be inferred that no changes occurred in this short period. The follow-up
at 6 months could be a short window. However, systemic inflammation is resolved one-month post
surgery; thus, the systemic alteration caused by the cardiac surgery should have not influenced
the results [48]. Finally, circulating markers of oxidative stress and endothelial dysfunction could
overlap. However, our analysis included more than one marker already linked to oxidative stress or
endothelial dysfunction.
5. Conclusions
Overall, the results obtained in this study highlight the ability of mitral valve surgery to completely
restore the increased oxidative stress levels evidenced in MVP patients. Conversely, the impairment in
endothelial function still present six months after surgical procedure draws special attention to the
need of studies aimed to dissect the molecular mechanisms of MVP.
In conclusion, our data suggest that endothelial dysfunction is not resolved by mitral valve
surgery. Further studies aimed to highlight the presence of a causal link between endothelial function
and mitral valve prolapse have to be conducted in order to define specific pharmacological treatments
able to prevent disease progression.
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